[1]Kim H,Lee JH,Joo YD,et al.Prospective,multicenter,phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia:a comparison with a higher dosage trial[J].Acta Haematol,2014,132(1):87-96.
[2]Sepehrizadeh Z,Mohammadi M,Emami A,et al.Assessment of cytokine expression profile in acute myeloid leukemia patients before and after chemotherapy[J].Turk J Haematol,2014,31(2):149-154.
[3]Yu Dan,Zhang Nian,Yi Xue,et al.Therapeutic effect of FLAG regime and MEA regime on refractory and relapse acute leukemia[J].Journal of Chinese Practical Diagnosis and Therapy,2013,27(11):1076-1081.[余丹,张念,易雪,等.FLAG和MEA方案治疗难治复发性急性髓系白血病疗效分析[J].中华实用诊断与治疗杂志,2013,27(11):1076-1081.]
[4]Zhang Liang,Zhou Hui,Chen Xiaohui.Efficacy and safety of MEA compared with FLAG in the treatment of refractory and relapsed acute myeloid leukemia[J].Practical Pharmacy And Clinical Remedies,2014,17(11):1500-1503.[章亮,周晖,陈小会.MEA与FLAG方案治疗难治性复发性急性髓系白血病疗效及安全性分析[J].实用药物与临床,2014,17(11):1500-1503.]
[5]Li Weiming,Zhang Min,He Jing,et al.Clinical observation of FLAG regime and MEA regime on refractory and relapse acute leukemia[J].Clinical Focus,2006,21(7):500-501.[黎纬明,张敏,何静,等.FLAG与MEA方案治疗复发难治成人急性髓细胞白血病的临床观察[J].临床荟萃,2006,21(7):500-501.]
[6]Zhang Chunmei,Sun Zhaogang,Bai Guanchen,et al.Effect comparison of FLAG regime and MEA regime on refractory and relapse acute leukemia[J].Medical Journal of Shandong,2012,52(11):60-61.[张春梅,孙兆刚,白观臣,等.FLAG方案及MEA方案治疗难治性和复发性AML的效果比较[J].山东医药,2012,52(11):60-61.]
[7]Liu Hui.Comparison on therapeutic effect of FLAG regime and MEA regime on refractory and relapse acute leukemia[J].Journal of Modern Medicine and Health,2013,29(10):1520-1521.[刘慧.FLAG方案和MAE方案治疗难治复发急性髓系白血病疗效比较[J].现代医药卫生,2013,29(10):1520-1521.]
[8]Liao Yongmei,Wang Lin,He Xuehua.Therapeutic effect of FLAG regime and MEA regime on refractory and relapse acute leukemia[J].Military Medical Journal of South China,2014,28(8):835-836.[廖永梅,王淋,何雪花.FLAG方案及MAE方案治疗难治性复发性急性髓系白血病的疗效分析[J].华南国防医学杂志,2014,28(8):835-836.]
[9]Zhang Zhinan,Shen Ti.The third edition blood disease diagnostic and curative standard[J].Beijing:Science Press,2007:172-176.[张之南,沈悌.血液病诊断及疗效标准[J].北京:北京科学技术出版社,2007:172-176.]
[10]O'Donnell MR,Tallman MS,Abboud CN,et al.Acute myeloid leukemia,version 3.2017,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2017,15(7):926-957.
[11]Leukemia and Lymphoma Group,Chinese Society of Hematology,Chinese Medical Associatino.The guidelines for diagnosis and treatment of acute myelogenous leukemia(relapse/refractory) in China (2017)[J].Chin J Hematol,2017,38(3):183-184.[中华医学会血液学分会白血病淋巴瘤学组.复发难治性急性髓系白血病中国诊疗指南(2017年版)[J].中华血液学杂志,2017,38(3):183-184.]
[12]Muluneh B,Buhlinger K,Deal AM,et al.A comparison of clofarabine-based (GCLAC) and cladribine-based (CLAG) salvage chemotherapy for relapsed/refractory AML[J].Clin Lymphoma Myeloma Leuk,2018,18(1):e13-e18.
[13]Fiegl M,Unterhalt M,Kern W,et al.Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia:a randomized trial of the AMLCG[J].Leukemia,2014,28(5):1001-1007.
[14]Camera A,Rinaldi CR,Palmieri S,et al.Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients[J].Ann Hematol,2009,88(2):151-158.
[15]Borthakur G,Kantarjian H,Wang X,et al.Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine,cytarabine,and granulocyte colony-stimulating factor results in improved event-free survival[J].Cancer,2008,113(11):3181-3185.
[16]Claus R,Wilop S,Hielscher T,et al.A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR[J].Epigenetics,2012,7(7):772-780.
[17]Ge Jian,Zeng Qingshu,Yang Mingzhen,et al.The therapeutic effect of CAG regimen and FLAG regimen on patients with refractory or relapsed acute myeloid leukemia[J].Anhui Medical Journal,2012,33(3):268-270.[葛健,曾庆曙,杨明珍,等.CAG与FLAG方案治疗难治或复发急性髓系白血病的疗效初步研究[J].安徽医学,2012,33(3):268-270.]
[18]Lee SS,Lee JH,Kim DY,et al.Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia[J].Leuk Res,2009,33(4):511-517.
[19]Halpern AB,Othus M,Huebner EM,et al.Mitoxantrone,etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms:a phase 1/2 study[J].Leukemia,2017,31(12):2560-2567.
[20]Schlenk RF,Muller-Tidow C,Benner A,et al.Relapsed/refractory acute myeloid leukemia:any progress[J]?Curr Opin Oncol,2017,29(6):467-473.